Navigation Links
Study Confirms that OrbusNeich's Genous™ Stent Effectively Captures Circulating Endothelial Progenitor Cells to Accelerate Re-Endothelialization and Decrease Thrombogenicity
Date:7/11/2011

HONG KONG, July 11, 2011 /PRNewswire/ -- OrbusNeich today announced that data from an ex vivo arteriovenous (AV) shunt model of human circulating blood, in addition to results from three preclinical studies, demonstrated that the Genous Stent effectively captures circulating CD34+ endothelial progenitor cells (EPCs) leading to accelerated re-endothelialization and decreased thrombogenicity compared to bare metal stents (BMS). These mechanistic data were published as an e-publication on the European Heart Journal website.

Data from the ex vivo human AV shunt study showed that EPC deposition on the struts of the Genous Stent was enhanced by 32.5 percent compared to BMS. In addition, the expression of specific endothelial markers increased significantly in cells deposited on the Genous Stent compared to those on the BMS. The data also showed a significant decrease in the expression of thrombotic markers associated with Genous.

"These data demonstrate the effectiveness of the capture of CD34+ cells for endothelialization and the prevention of thrombosis," said Eric J. Duckers, M.D., Ph.D., of the Thoraxcenter at Erasmus University Medical Center in Rotterdam, The Netherlands, and senior author of the publication. "This mechanism of early endothelialization supports the usage of Genous' unique EPC capture technology especially for patients who are at higher risk of thrombosis."

For the ex vivo human study, 15 patients undergoing coronary angiography received an extracorporeal femoral AV shunt containing a Genous Stent and a BMS, which were exposed to circulating blood for up to 120 minutes. The cell depositions on the struts were determined by confocal and scanning electron microscopic analysis (SEM). Expression of endothelial and thrombotic markers was determined using quantitative polymerase chain reaction (qPCR).

"We were able to see a significant difference between the Genous Stent and the bare metal stent in
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PRINCETON, N.J. , Dec. 24, 2014 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today that on ... registered public offering. The Company raised ... offering and intends to use the net proceeds ...
(Date:12/24/2014)...  Diplomat Pharmacy, Inc. (NYSE: DPLO ), ... announce Jennifer Hagerman , Pharm.D., AE-C, senior director ... as the president of the Michigan Pharmacists Association on ... place Feb. 28, 2015, at the MPA Annual Convention ... Center in Detroit, Michigan . Hagerman ...
(Date:12/24/2014)... PuraMed BioScience®, Inc., (OTC Pink: PMBS), a ... healthcare products, announced it received the initial funding to ... headache relief product, for planned distribution to 1,000 medical ... , Washington State , and ... H Advanced headache relief gel formulation completed, PuraMed BioScience ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... Calif., April 4, 2011 ICU Medical, ... three different clinical studies presented at the Annual Scientific ... (SHEA) April 1-4 in Dallas showed that the MicroCLAVE ... of bacterial contamination and limit the incidence of hospital-acquired ...
... Hospital is planning to leverage Prognosis ChartAccess® Comprehensive EHR ... improving clinical care, meeting the government,s meaningful use requirements, ... Texas Regional Health Information Organization (RHIO). "Like ... at the same time meet the government,s requirements for ...
Cached Medicine Technology:Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections 2Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections 3Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections 4Hamlin Memorial Hospital Selects Prognosis ChartAccess® Comprehensive EHR 2Hamlin Memorial Hospital Selects Prognosis ChartAccess® Comprehensive EHR 3
(Date:12/25/2014)... York (PRWEB) December 25, 2014 Product ... DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to ... According to an Order issued in the U.S. District ... Court will convene an open conference on January 7, ... United States Courthouse in West Palm Beach, Florida. The ...
(Date:12/25/2014)... December 25, 2014 The short film “Color ... created in honor of a true 9/11 hero, Welles Remy ... festivals including the 24 hours of Nuremberg International Short Film ... , Actress, screenwriter and director Luciana Lagana ... film together with her husband, Gregory Graham - ...
(Date:12/25/2014)... December 25, 2014 When head lice hits ... in a frenzy to get rid of it while keeping ... in Coral Gables now have the solution right in their ... clinic location, Lice Troopers provides full spectrum head lice screening ... Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, ...
(Date:12/25/2014)... Overeating is common during the holidays, but there are strategies ... "Don,t arrive at a party hungry. It may seem ... attending a party, but deprivation leads to hunger, and hunger ... Hospital in Mount Kisco, N.Y., said in a hospital news ... and even to have a snack before attending a party ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... continue to move forward in a number of multidistrict ... of West Virginia, Bernstein Liebhard LLP reports. According to ... is scheduled to convene a Joint Status Conference in ... 10:00 a.m. Parties have been directed to submit a ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... 2 Regarding the completely fabricated,item about GO3 ... July 14, 2008,edition of Star magazine, none of ... were contacted by the magazine prior to publication., ... reviewing its legal options and will vigorously pursue ...
... distant sites has a poor prognosis, but an experimental drug ... in some patients, a research team led by investigators from ... in the July 3rd edition of The New England ... is a VEGF inhibitor, a biologic agent that targets receptors ...
... light of today,s,announcement that Attorney General Mike Cox is ... the Coalition for a Fair and,Competitive Insurance Market is ... Blue Cross Blue Shield of Michigan (BCBSM) to use ... and insurance., "We were confident when we raised ...
... a genetic mutation that improves response to therapy , , ... that inhibits tumor blood vessel formation slows the progression ... study finds. , Of the 93 patients with rapidly ... with motesanib diphosphate. Of those 49 patients, 14 percent ...
... LAVAL, QC, July 2 /PRNewswire-FirstCall/ - Labopharm Inc. ... submitted a complete response to,the Food and Drug ... M.D., the FDA,s Deputy Director, Center for Drug ... the regulatory path towards,potential U.S. approval of the ...
... MD, will join three other physicians as a 2008 American Orthopaedic ... ... Orlando, Florida (PRWEB) July 2, 2008 -- University of ... physicians as a 2008 American Orthopaedic Society for Sports Medicine ...
Cached Medicine News:Health News:GO3 Statement Regarding Erroneous Coverage in Star Magazine 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 3Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 4Health News:Coalition Calls on MI Legislature to Abandon Blue Cross Legislation 2Health News:New Drug Slows Thyroid Cancer 2Health News:Labopharm Submits Complete Response to FDA as a Result of Outcome of Appeal Process for Once-Daily Tramadol 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 3
... Ultrasonic Nebulizer has an easy-to-operate ... portable, and lightweight unit is ... quite treatments operating on AC ... auto adapter. , ,Optional ...
With ten colors available, Spectrums line of Color-Coded Fiberoptic Light Cables makes it easy to track by department....
Lumitex® LightMat® Surgical Illuminator improves visualization in deep cavity surgery. Flexible and malleable, it attaches easily to most retractors, bringing bright, cool area lighting where...
... The new UltraLux headlight gives you the ... can afford. It offers the illumination, comfort and ... The UltraLux is our lightest headlight. It features ... 130 for unsurpassed comfort and flexibility. Now when ...
Medicine Products: